Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 15, 2019 07:00 ET | Source: Auris Medical AG

Auris Medical Provides Business Update and Reports First Half 2019 Financial Results

Hamilton, Bermuda, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Enrollment of first patient in TRAVERS Phase 2 trial with AM-125 in acute vertigoEnrollment completed in Phase 1b trial with AM-201 in...
July 30, 2019 08:30 ET | Source: Auris Medical AG

Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo

Hamilton, Bermuda, July 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
July 03, 2019 09:00 ET | Source: Auris Medical AG

Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain

Hamilton, Bermuda, July 03, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
May 23, 2019 09:00 ET | Source: Auris Medical AG

Auris Medical Holding Ltd Provides Corporate Update

Hamilton, Bermuda, May 23, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
May 20, 2019 08:45 ET | Source: Auris Medical AG

Auris Medical Holding Ltd Regains Compliance with Nasdaq Minimum Bid Price Rule

Hamilton, Bermuda, May 20, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
May 15, 2019 16:15 ET | Source: Auris Medical AG

Auris Medical Announces Closing of Public Offering of Common Shares

Hamilton, Bermuda, May 15, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
May 15, 2019 09:00 ET | Source: Auris Medical AG

Auris Medical Announces Closing of Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD

Hamilton, Bermuda, May 15, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
May 13, 2019 08:30 ET | Source: Auris Medical AG

Auris Medical Holding Ltd.:

Hamilton, Bermuda, May 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
May 07, 2019 09:00 ET | Source: Auris Medical AG

Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain

Hamilton, Bermuda, May 07, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
April 30, 2019 08:30 ET | Source: Auris Medical AG

Auris Medical Announces Reverse Stock Split

Hamilton, Bermuda, April 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right